Neuphoria Therapeutics (NEUP) Total Liabilities (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Total Liabilities for 7 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Liabilities rose 14.19% year-over-year to $5.4 million in Q1 2026; TTM through Mar 2026 was $5.4 million, a 14.19% increase from a year earlier, with the FY2025 full-year figure at $9.6 million, down 5.63% from the prior year.
• Total Liabilities was $5.4 million for Q1 2026 at Neuphoria Therapeutics, down from $6.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $14.8 million in Q3 2025 and troughed at -$19.5 million in Q4 2023.
• A 5-year average of $1.5 million and a median of $5.8 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 153.7% in 2025, down 5.63% in 2025.
• Over 5 years, Total Liabilities stood at $6.0 million in 2022, then sank by 424.16% to -$19.5 million in 2023, then surged by 122.67% to $4.4 million in 2024, then soared by 56.04% to $6.9 million in 2025, then retreated by 21.92% to $5.4 million in 2026.
• The last three Total Liabilities figures came in at $5.4 million (Q1 2026), $6.9 million (Q4 2025), and $14.8 million (Q3 2025), per Business Quant data.